Featured Story | By Nick Paul Taylor Chalk up a pyrrhic victory for the Principia Biopharma short sellers. After arguing Principia’s pipeline was worthless, short sellers saw Sanofi snap up the biotech at a hefty premium in a $3.7 billion deal. Now, rilzabrutinib, one of Principia’s key candidates, has flunked its first major clinical test. read more |
| |
|---|
|
Top Stories By Ben Adams After riding high in 2021 on some broadly positive COVID data and high hopes for a speedy authorization, Humanigen has come crashing back down to earth. read more By Ben Adams Eli Lilly is doubling down on RNA research as it pens another major biobucks pact with a small but promising biotech in the gene-silencing space. read more By Kyle LaHucik Founded by ex-Dermira founders, Evommune has secured $83 million in series A financing to advance three programs in-licensed from Eli Lilly's Dermira and another from Axcelead. The programs tackle atopic dermatitis, psoriasis, rosacea and itching and the first is slated to enter the clinic by year's end. read more By Nick Paul Taylor Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at for almost 30 years. read more By Amirah Al Idrus On the back of a busy year, Mammoth Biosciences is getting a $195 million boost, which will ramp up the development of its gene-editing pipeline, as well as fuel its work in CRISPR-based diagnostics. read more By Ben Adams Lycia Therapeutics has grabbed a $70 million series B for its next-generation degradation approach to zero in on the untapped extracellular proteome that could target a host of diseases. read more By Annalee Armstrong Lexeo Therapeutics isn’t wasting any time. The gene therapy biotech, which emerged in January with an all-star team of industry veterans, has raised $100 million to advance a pipeline of treatments for genetic cardiovascular and central nervous system conditions. read more By Kyle LaHucik iECURE is emerging from stealth with $50 million and a mission to go after the "holy grail" of gene editing with an in vivo approach that is mutation agnostic. The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at the University of Pennsylvania. read more By Emmy Lucas Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic along with an accompanying radiotracer diagnostic imaging agent. read more By Andrea Park The defense’s opening statement described Holmes as a pioneering leader who shared the “fake it ‘til you make it” mentality typical of other Silicon Valley startups but, due to her lack of experience, “naively underestimated” some of the challenges that arose in Theranos’ path to scientific viability. read more By Ben Adams Cancer trials typically have to be done within a hospital or community healthcare setting, but Science 37 and Roche’s genomics unit Foundation Medicine are teaming up to move some of this to an at-home setting. read more By Arlene Weintraub A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules. The treatment suppressed tumors in mouse models of colon cancer and melanoma, and it worked even better when combined with checkpoint inhibiting drugs, they reported in a new study. read more By Anastassia Gliadkovskaya The virtual care center will serve patients in Sanford Health’s network, and will also be the home base of several innovation, education and research initiatives aimed at advancing digital healthcare. read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
